Table 2.
ORR, PFS and OS in PS patients receiving subsequent platinum by BRCA mutation.
| Total | BRCA MUTANT |
BRCA WT/Others | p | |
|---|---|---|---|---|
| n = 74 | n = 35 | n = 39 | ||
| Best response to CT administered after PARPi progression, n (%): | 0 | 0.004 | ||
| CR | 6 (8.1%) | 5 (14.3%) | 1 (2.6%) | |
| PR | 25 (33.8%) | 9 (25.7%) | 16 (41.0%) | |
| SD | 20 (27.0%) | 5 (14.3%) | 15 (38.5%) | |
| PROG | 23 (31.1%) | 16 (45.7%) | 7 (17.9%) | |
| OS * | 20.6 (13.6–28.9) | 16.4 (9.3–27.5) | 24.2 (17.2, NR) | 0.036 |
| PFS * | 6.6 (6–9.2) | 3.5 (2.5–8.6) | 7.5 (6.5–10.1) | 0.030 |
* excluding patients included in the OREO study.